Meeting
2014 ASCO Annual Meeting
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.
Authors
Marzia Del Re
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Marzia Del Re , Lorenza Landi , Marcello Tiseo , Andrea Camerini , Iacopo Petrini , Alessandro Inno , Valentina Citi , Jessica Salvini , Gabriele Minuti , Enrico Vasile , Alfredo Falcone , Stefania Gori , Domenico Amoroso , Andrea Ardizzoni , Federico Cappuzzo , Romano Danesi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Genomic and Epigenomic Biomarkers
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 11056)
DOI
10.1200/jco.2014.32.15_suppl.11056
Abstract #
11056
Poster Bd #
338
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Targeting c-Met overexpression for overcoming acquired resistance to EGFR TKIs in NSCLC.
First Author: Lanying Gou Jr.
Poster
2013 ASCO Annual Meeting
A retrospective analysis of the prevalence of EGFR or KRAS mutations in patients (pts) with crizotinib-naïve and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC).
First Author: Justin F. Gainor
Poster
2011 ASCO Annual Meeting
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.
First Author: J. Yang
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura